Skip to main content
Premium Trial:

Request an Annual Quote

Two FDA Officials to Depart

Two US Food and Drug Administration officials who oversee vaccines are to leave in the coming weeks, the Washington Post reports.

Marion Gruber, director of the FDA's Office of Vaccines Research and Review, is to leave the agency by the end of October, while Philip Krause, deputy director there, plans to depart in November, it adds. According to the Post, Peter Marks, director of the Center for Biologics Evaluation and Research at FDA, is to serve as the acting head of the vaccine office while a search for a new permanent one is conducted.

The Post notes that these departures come as the agency faces pressure to authorize SARS-CoV-2 vaccines for use in children and to allow booster shots. Endpoints News reports that both Gruber and Krause were "frustrated" with the involvement of the Centers for Disease Control and Prevention in decisions they thought fell under the FDA's purview and "the White House getting ahead of FDA on booster shots."

An FDA spokesperson says the departures of Gruber and Krause won't slow the agency's work, the Post adds. "We are confident in the expertise and ability of our staff to continue our critical public health work, including evaluating COVID-19 vaccines," Stephanie Caccomo, the FDA spokesperson, says in a statement according to the Post.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.